Protein-based therapeutic approaches targeting death receptors

Détails

ID Serval
serval:BIB_C64A159D235E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Protein-based therapeutic approaches targeting death receptors
Périodique
Cell Death and Differentiation
Auteur(s)
French  L. E., Tschopp  J.
ISSN
1350-9047 (Print)
Statut éditorial
Publié
Date de publication
01/2003
Volume
10
Numéro
1
Pages
117-23
Notes
Journal Article
Review --- Old month value: Jan
Résumé
Death receptors (DRs) are a growing family of transmembrane proteins that can detect the presence of specific extracellular death signals and rapidly trigger cellular destruction by apoptosis. Eight human DRs (Fas, TNF-R1, TRAMP, TRAIL-R1, TRAIL-R2, DR-6, EDA-R and NGF-R) have been identified. The best studied to date is Fas (CD95). Expression and signaling by Fas and its ligand (FasL, CD95L) is a tightly regulated process essential for key physiological functions in a variety of organs, including the maintenance of immune homeostasis. Recently, strong evidence has shown that dysregulation of Fas expression and/or signaling contributes to the pathogenesis of tissue destructive diseases such as graft-versus-host disease, toxic epidermal necrolysis, multiple sclerosis and stroke. With these new developments, strategies for modulating the function of Fas signaling have emerged and provided novel protein-based therapeutic possibilities that will be discussed herein. Selective triggering of DR-mediated apoptosis in cancer cells is an emerging approach that is being intensely investigated as a mode of cancer therapy. Local administration of Fas agonists, and more promisingly, systemic use of soluble recombinant forms of TRAIL have shown efficacy in preclinical models of the disease. Developments in this field that may have important clinical implications for the treatment of cancer are reviewed.
Mots-clé
Animals Antigens, CD95/*drug effects/metabolism Antineoplastic Agents/therapeutic use Apoptosis/*drug effects/physiology Apoptosis Regulatory Proteins Eukaryotic Cells/*drug effects/metabolism Fas Ligand Protein Humans Membrane Glycoproteins/*agonists/therapeutic use Neoplasms/*drug therapy/genetics/metabolism TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2008 16:19
Dernière modification de la notice
09/05/2019 1:02
Données d'usage